Published in Clin Cancer Res on May 15, 2008
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Revealing global regulatory perturbations across human cancers. Mol Cell (2009) 2.62
Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol (2010) 1.87
Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol (2009) 1.78
The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. Br J Cancer (2012) 1.25
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol (2014) 1.18
Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer. Chin J Cancer Res (2012) 1.01
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res (2010) 0.99
Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecol Oncol (2010) 0.97
Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival. Virchows Arch (2012) 0.93
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol (2010) 0.92
Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer. J Exp Clin Cancer Res (2010) 0.90
TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. BMC Cancer (2010) 0.88
Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment. J Control Release (2014) 0.85
Expression of hypoxic markers and their prognostic significance in soft tissue sarcoma. Oncol Lett (2015) 0.83
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma. Int J Clin Oncol (2010) 0.83
Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers. Korean J Pathol (2012) 0.82
Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma. PLoS One (2008) 0.82
Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue. PLoS One (2014) 0.81
Antivascular therapy for epithelial ovarian cancer. J Oncol (2009) 0.80
Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors. Virchows Arch (2011) 0.79
Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance. Iran J Cancer Prev (2015) 0.78
Volatile anaesthetics enhance the metastasis related cellular signalling including CXCR2 of ovarian cancer cells. Oncotarget (2016) 0.77
Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro. J Transl Med (2016) 0.77
TROP-1/Ep-CAM and CD24 are potential candidates for ovarian cancer therapy. Int J Clin Exp Pathol (2015) 0.77
Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment. Am J Cancer Res (2016) 0.76
Melatonin Reduces Angiogenesis in Serous Papillary Ovarian Carcinoma of Ethanol-Preferring Rats. Int J Mol Sci (2017) 0.75
Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells. Clin Epigenetics (2015) 0.75
VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients. Oncotarget (2017) 0.75
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology (2008) 2.83
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res (2008) 1.54
Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer (2006) 1.52
NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res (2009) 1.50
The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer (2007) 1.49
Alloantibody to a Bw4 epitope in a Bw4+B*27: 05 patient. Transplantation (2014) 1.39
Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. J Immunol (2011) 1.32
Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut (2010) 1.32
Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer (2005) 1.25
Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer (2006) 1.20
ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients. Int J Cancer (2010) 1.17
Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol (2014) 1.11
High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res (2005) 1.11
The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer. World J Surg Oncol (2007) 1.11
Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res (2007) 1.10
Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res (2007) 1.04
Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun (2007) 1.04
Human NK cells proliferate and die in vivo more rapidly than T cells in healthy young and elderly adults. J Immunol (2011) 1.03
Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. Clin Cancer Res (2007) 1.02
The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer (2007) 1.01
Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol Immunother (2005) 1.00
Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55. J Biol Chem (2007) 0.99
Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer. Int J Gynecol Pathol (2010) 0.97
Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunol Immunother (2006) 0.96
Loss of CD55 is associated with aggressive breast tumors. Clin Cancer Res (2004) 0.95
Costimulation via CD55 on human CD4+ T cells mediated by CD97. J Immunol (2006) 0.94
The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression. Virchows Arch (2011) 0.93
Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival. Virchows Arch (2012) 0.93
The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development. Proc Natl Acad Sci U S A (2008) 0.93
Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World J Surg Oncol (2005) 0.92
Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer. J Cell Mol Med (2012) 0.91
High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment. PLoS One (2012) 0.91
Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. Hum Pathol (2013) 0.91
Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla. BMC Cancer (2012) 0.88
Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)? Cancer Immunol Immunother (2004) 0.88
DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells. Eur J Immunol (2010) 0.87
The ataxia telangiectasia mutated kinase pathway regulates IL-23 expression by human dendritic cells. J Immunol (2013) 0.86
Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy. Free Radic Biol Med (2010) 0.86
Comparison of the immune response to a self antigen after DNA immunisation of HLA*A201/H-2Kb and HHD transgenic mice. Vaccine (2004) 0.85
CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype. J Immunol (2013) 0.83
The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer. Mod Pathol (2012) 0.83
Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature. Am J Surg Pathol (2012) 0.82
Using monoclonal antibodies to stimulate antitumor cellular immunity. Expert Rev Vaccines (2011) 0.82
T cell density and location can influence the prognosis of ovarian cancer. Pathol Oncol Res (2009) 0.81
A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Cancer Res (2006) 0.81
Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients. World J Gastroenterol (2006) 0.81
Redox protein expression predicts radiotherapeutic response in early-stage invasive breast cancer patients. Int J Radiat Oncol Biol Phys (2011) 0.80
Differential transcription factor use by the KIR2DL4 promoter under constitutive and IL-2/15-treated conditions. J Immunol (2012) 0.80
FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol (2009) 0.78
Expression of angiogenic chemokines in ovarian clear cell carcinoma. J Obstet Gynaecol Res (2012) 0.78
Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses. Expert Opin Biol Ther (2010) 0.78
Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival. Int J Cancer (2008) 0.77
Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2. Int J Cancer (2004) 0.77
Psychosocial resources, aging, and natural killer cell terminal maturity. Psychol Aging (2012) 0.76
Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29. PLoS One (2013) 0.76
The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis. J Cancer Res Clin Oncol (2014) 0.76
A Prebiotic Galactooligosaccharide Mixture (B-GOS) Reduces Severity of Hyperpnea-Induced Bronchoconstriction and Airway Inflammation: 1647 Board #300 June 2, 9: 00 AM - 10: 30 AM. Med Sci Sports Exerc (2016) 0.75
International conference: progress in vaccination against cancer (PIVAC) 2002, Nottingham, UK. Cancer Immunol Immunother (2003) 0.75
The use of reverse immunology to identify HLA-A2 binding epitopes in Tie-2. Cancer Immunol Immunother (2006) 0.75
The periodontal war: microbes and immunity. Periodontol 2000 (2017) 0.75
Comparison of tissue effects quantified histologically between PlasmaJet coagulator and Helica thermal coagulator. Arch Gynecol Obstet (2012) 0.75